Harmony Biosciences Holdings Cash Flow Reinvestment Rate
Harmony Biosciences Holdings cash flow reinvestment rate. Harmony Biosciences Holdings (HRMY) has a Cash Flow Reinvestment Rate of 1.42x as of June 2026, reinvesting $131.50 Million (capex $0.00 plus investments $-131.50 Million) from operating cash flow of $92.43 Million. Explore HRMY operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Harmony Biosciences Holdings (2021–2025)
Cash flow reinvestment rate of Harmony Biosciences Holdings from 2021 to 2025. Historical reinvestment intensity for Harmony Biosciences Holdings across 5 annual periods. Explore HRMY capex reinvestment rate to see what proportion of operating cash flow is directed to capital expenditures.
Harmony Biosciences Holdings Cash Flow Reinvestment Rate by Year (2021–2025)
Harmony Biosciences Holdings cash flow reinvestment rate by year from 2021 to 2025. Year-by-year capital reinvestment analysis for Harmony Biosciences Holdings. For the full cash flow conversion analysis, see HRMY cash generation efficiency.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.02x | $5.40 Million | $348.20 Million | $310.00K | ▼ -95.0% |
| 2024 | 0.31x | $68.64 Million | $219.82 Million | $1.15 Million | ▲ +19.0% |
| 2023 | 0.26x | $57.58 Million | $219.39 Million | $312.00K | ▼ -73.3% |
| 2022 | 0.98x | $142.00 Million | $144.47 Million | $172.00K | ▼ -3.7% |
| 2021 | 1.02x | $100.60 Million | $98.56 Million | $298.00K | — |